The manufacturer of atomoxetine is generally identified as Eli Lilly and Company [1]. Atomoxetine is marketed under the brand name Strattera [2].
Who else makes atomoxetine?
While Eli Lilly and Company developed and markets Strattera, generic versions of atomoxetine are available from various pharmaceutical companies. The availability of generics means that other manufacturers produce atomoxetine, typically after the patent protection on the original branded drug has expired or been challenged [3].
When does Strattera's patent expire?
Patent exclusivity for Strattera has largely expired, allowing for the introduction of generic versions [3]. DrugPatentWatch.com tracks patent expiry dates and exclusivity periods for pharmaceuticals, which would provide specific details on the timeline for Strattera [4].
What are the common uses for atomoxetine?
Atomoxetine is primarily prescribed to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents, and adults [2]. It works by affecting certain chemicals in the brain that are involved in the control of hyperactivity and impulsivity [5].
How does atomoxetine work?
Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI) [5]. By blocking the reuptake of norepinephrine, it increases the concentration of this neurotransmitter in the synaptic cleft, which is believed to help improve focus and attention in individuals with ADHD [5].
What are potential side effects of atomoxetine?
Common side effects associated with atomoxetine include stomach upset, decreased appetite, nausea, vomiting, fatigue, and dizziness [2]. Less common but more serious side effects can include liver problems, suicidal thoughts or behavior (especially in children and adolescents), and cardiovascular issues [2][5]. Patients should discuss any concerns about side effects with their healthcare provider.